



**Aarey**

**DRUGS & PHARMACEUTICALS LTD.**

**MANUFACTURERS OF BULK DRUGS &  
DEALERS OF CHEMICAL & SOLVENTS**

GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538

HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C, TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

Date: 10<sup>th</sup> August, 2021

<b>BSE Limited</b> The Manager, Corporate Service Department P.J. Towers, Dalal Street, Mumbai- 400 001  <b>Scrip Code: 524412</b>	<b>National Stock Exchange of India Limited</b> Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai – 400051  <b>NSE Symbol: AAREYDRUGS</b>
--	---

Sub: Unaudited Financial Results for the Quarter ended 30<sup>th</sup> June, 2021.

Dear Sir/Madam,

Pursuant to the Listing agreement we are enclosing herewith the Unaudited financial results for the quarter ended 30<sup>th</sup> June, 2021 with Limited Review Report.

Please take on record of the same and oblige.

Thanking you,

Yours Faithfully,

**For Aarey Drugs & Pharmaceuticals Ltd**

  
Mihir R Ghatalia  
Managing Director  
DIN: 00581005



Encl.: a/a

**Aarey****DRUGS & PHARMACEUTICALS LTD.****MANUFACTURERS OF BULK DRUGS & DEALERS OF CHEMICAL & SOLVENTS**GST No. : 27AAACA5253A1Z9  
CIN No. : L99999MH1990PLC056538HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP, TELLI GALLI, ANDHERI - (E), MUMBAI - 400 069 INDIA . TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com  
REGD. OFFICE & FACTORY : E-34, M.I.D.C.,TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL. : (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com

## STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30TH JUNE, 2021

(Rs.in Lakhs excluding EPS)

Sr.No.	PARTICULARS	Quarter ended		Year Ended	
		30.06.2021 (Unaudited)	31.03.2021 (Audited)	30.06.2020 (Unaudited)	31.03.2021 (Audited)
I)	Revenue from Operations	9,751.78	17,825.17	2,521.77	34,841.64
II)	Other Income	67.08	163.80	73.74	701.46
III)	<b>Total Income (I+II)</b>	<b>9,818.86</b>	<b>17,988.97</b>	<b>2,595.51</b>	<b>35,543.10</b>
IV)	Expenses:				
	Cost of Materials Consumed	8,452.69	16,349.02	2,158.80	33,925.48
	Changes in Inventories of Finished goods, Work in progress and Stock in trade	837.56	1,152.83	101.10	(146.46)
	Employee Benefit Expenses	10.85	39.55	-	39.55
	General Administrative Expense	17.47	165.45	24.35	225.33
	Selling and Distribution Exp	111.37	36.15	21.21	333.86
	Depreciation and Amortization Expense	40.00	24.99	22.35	92.04
	Finance Cost	47.09	55.57	46.64	243.16
	Other Expenses	28.97	-153.96	65.21	-
	<b>Total Expenses (IV)</b>	<b>9,546.00</b>	<b>17,669.62</b>	<b>2,439.66</b>	<b>34,712.96</b>
V)	<b>Profit (+) / Loss (-) before Exceptional and Tax (III-IV)</b>	<b>272.86</b>	<b>319.36</b>	<b>155.85</b>	<b>830.14</b>
VI)	Exceptional Items	-	-	-	-
VII)	<b>Profit (+) / Loss (-) before Tax (V-VI)</b>	<b>272.86</b>	<b>319.36</b>	<b>155.85</b>	<b>830.14</b>
VIII)	Tax Expenses				
	a) Current Tax	(22.00)	(166.40)	(20.00)	(166.40)
	b) Deferred Tax	-	(12.31)	-	(12.31)
IX)	<b>Profit (+) / Loss (-) for the period (VII-VIII)</b>	<b>250.86</b>	<b>140.65</b>	<b>135.85</b>	<b>651.43</b>
X)	Other Comprehensive Income (OCI)				
i.	Items that will not be reclassified to Profit and Loss	-	-	-	-
ii.	Income Tax relating to Items that will not be reclassified to Profit or Loss	-	-	-	-
iii.	Items that will be reclassified to Profit or Loss	-	-	-	-
iv.	Income Tax relating to Items that will be reclassified to Profit or Loss	-	-	-	-
	<b>Total Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
XI)	<b>Total Comprehensive Income for the period</b>	<b>250.86</b>	<b>140.65</b>	<b>135.85</b>	<b>651.43</b>
	Earnings Per Share				
	a) Basic EPS (Rs.)	1.07	0.60	0.58	2.79
	b) Diluted EPS (Rs.)	1.07	0.60	0.58	2.79
	Number of Shares	23,384,684	23,384,684	23,384,684	23,384,684
	Percentage of Shareholding	100.00%	100.00%	100.00%	100.00%
	Paid up Equity Share Capital (Face Value of Rs.10/ each)	2,338.47	2,338.47	2,338.47	2,338.47

## Notes :

- The unaudited financial results for the quarter ended 30th June, 2021 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10th August, 2021. The unaudited Financial Results are prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013.
- The figure for the quarter ended 31st March 2021 are the balancing figures between the audited financial figures in respect of the full financial year and unaudited published year to date financial figures upto 31st December 2020.
- The Company operates only in one segment i.e. Manufacturing and Trading of Drugs & Pharmaceutical and all other allied activities revolving around the same. As such there is no other separate reportable segment as defined by IND AS 108- "Operating Segments."
- Expenses in relation to Administration and Selling & distribution have been separately disclosed under the head "General Administrative Expense" and "Selling and Distribution Expense" respectively for fair disclosure purpose for all the periods type as per the judgement of the Company.
- The Figures of the previous year/period have been regrouped wherever necessary.

Place: Mumbai  
Date: 10th August, 2021By order of the Board of Directors  
For Aarey Drugs & Pharmaceuticals Limited  
(M. R. Ghatalla)  
Managing Director  
DIN: 00581005



Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended.

TO THE BOARD OF DIRECTORS  
AAREY DRUGS & PHARMACEUTICALS LTD

1. We have reviewed the accompanying statement of unaudited Financial Results of AAREY DRUGS & PHARMACEUTICALS LTD ("the Company") for the period ended June 30, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended, read with Circular No. CIR/CFD/CMD1/44/2019 dated 29th March 2019 ("the 'Circular'").
2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards ('Ind AS'), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

*for Motilal & Associates LLP*  
*Chartered Accountants*  
**ICAI FRN: 106584W/W100751**  
*(Formerly known as Motilal & Associates)*



**M H Jain**  
*Partner*  
**M. No. 036811**



**Place :** Mumbai  
**Date :** 10<sup>th</sup> August, 2021.

UDIN : 21036811 AAAA GA 3582

## Certificate of Managing Director (MD)

I, Mihir R. Ghatalia, Managing Director (MD) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30<sup>th</sup> June, 2021 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mihir R. Ghatalia

MD


Date: 10/08/2021

Place: Mumbai

## Certificate of Chief Financial Officer (CFO)

I, Mira R. Ghatalia, Chief Financial Officer (CFO) of Aarey Drugs & Pharmaceuticals Ltd., certify;

- 1) That I have reviewed the Unaudited Financial Statements for the quarter ended 30<sup>th</sup> June, 2021 and to the best of my knowledge and belief:
  - a) These financial results do not contain any materially untrue statement or omit any material fact nor contain statement that might be misleading, and
  - b) These financial statements present a true and fair view of the Company's affairs and are in compliance with the applicable laws and regulations.
- 2) That there are to the best of my knowledge and belief, no transactions entered into by the company during the quarter, which are fraudulent, illegal or violative of the Company's Code of Conduct.
- 3) That I accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the Company and I have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of internal controls, if any, of which I am aware and the steps that I have taken to rectify the identified deficiencies.



Mira R.. Ghatalia

CFO

Date: 10/08/2021

Place: Mumbai